Christopher Gallo holds a PhD in Biochemistry and Molecular Genetics. His practice is focused on patent litigation. Christopher's experience includes matters before federal district courts and the United States International Trade Commission in which he has been heavily involved in all aspects of litigation, from pre-filing investigation, through fact and expert-witness discovery, claim-construction, and trial. Christopher also has experience in patent reexaminations and in inter partes review proceedings before the Patent Trial and Appeal Board at the USPTO.
Prior to joining the firm, Christopher was an associate at Sterne, Kessler, Goldstein & Fox where he was a contributing author of Patent Office Litigation, Second Edition, published in 2017. He previously worked as a postdoctoral fellow at the Johns Hopkins University School of Medicine, where he investigated the role of RNA-protein complexes in regulating fertility and cell fate specification in the model organism Caenorhabditis elegans. Christopher's research involved both fixed and live imaging techniques, as well as the biochemical isolation and purification of RNA-protein complexes. His doctoral research focused on the role of nicotinamide in regulating gene silencing and lifespan in yeast.
Outstanding Article Award – Award for one of the top three submissions to the International Trade Commission Trial Lawyers Association’s 337 Reporter: Summer Associate Edition, November 2011
NIH-Ruth L. Kirschstein National Research Service Award (2007 – 2008)
NIH-Cellular and Molecular Biology Training Grant (2002 – 2004)
- Surveying the Landscape, Intellectual Property Magazine, September 29, 2020
- Method of Treatment Eligibility, Intellectual Property Magazine, January 9, 2020
- 3 Strategies to Manage Case Scope in ANDA Patent Litigation, Law360, December 10, 2019
- Curing the Drug Label as Prior Art Malady at the PTAB, IPWatchdog, November 13, 2019
- Fixing the Follow-On Insulin Regulatory Approval "Dead Zone", BioSimilar Development, September 4, 2019
- Axinn IP Update: FDA Issues Final Guidance on Interchangeability of Biologics, Axinn Update, May 14, 2019
- JD - George Washington University School of Law (2014)
- PhD, Biochemistry and Molecular Genetics - University of Virginia (2005)
- BS, Biology - Pennsylvania State University (2000)
- District of Columbia
- United States Patent and Trademark Office